1	Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza
2	Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial
3	
4	Benjamin J. Cowling ^{1,2} , Sook-San Wong ^{1,3} , Jefferson J. S. Santos ⁴ , Lisa Touyon ^{1,3} , Jordan
5	Ort ⁴ , Naiqing Ye ⁴ , Natalie K. M. Kwok ¹ , Faith Ho ¹ , Samuel M. S. Cheng ¹ , Dennis K. M. Ip ¹ ,
6	Malik Peiris ¹ , Richard J. Webby ⁵ , Patrick C. Wilson ⁶ , Sophie A. Valkenburg ^{3,7} , John S.
7	Tsang ⁸ , Nancy H. L. Leung ^{1,2} , Scott E. Hensley ⁴ , Sarah Cobey ⁹
8	
9	Affiliations:
10	1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
11	Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
12	Special Administrative Region, China
13	2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology
14	Park, New Territories, Hong Kong Special Administrative Region, China
15	3. HKU-Pasteur Research Pole, Li Ka Shing Faculty of Medicine, The University of Hong
16	Kong, Hong Kong Special Administrative Region, China
17	4. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,
18	Philadelphia, PA 19104
19	5. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN
20	38105
21	6. Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York,
22	NY 10021
23	7. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and
24	Immunity, University of Melbourne, Melbourne, Australia

- 8. Yale Center for Systems and Engineering Immunology and Department of Immunobiology,
- 26 Yale University School of Medicine, New Haven, CT 06520
- 9. Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637
- 28

29 Corresponding author:

- 30 Prof. Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The
- 31 University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong
- 32 Tel: +852 3917 6711; Email: <u>bcowling@hku.hk</u>
- 33
- 34 Word count (abstract): 312
- 35 Word count (main text): 3,473
- 36 Running head: Antibody responses after repeated influenza vaccination
- 37 Clinicaltrials.gov: NCT04576377
- 38
- 39

40 ABSTRACT

41	Background: Studies have reported that repeated annual vaccination may influence the
42	effectiveness of the influenza vaccination in the current season. The mechanisms underlying
43	these differences are unclear but might include "focusing" of the adaptive immune response
44	to older strains.
45	Methods: We established a 5-year randomized placebo-controlled trial of repeated influenza
46	vaccination (Flublok, Sanofi Pasteur) in adults 18-45 years of age. Participants were
47	randomized equally between five groups, with planned annual receipt of vaccination (V) or
48	saline placebo (P) as follows: P-P-P-V, P-P-V-V, P-P-V-V, P-V-V-V, or V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-
49	V. Serum samples were collected each year just before vaccination and after 30 and 182 days.
50	A subset of sera were tested by hemagglutination inhibition assays, focus reduction
51	neutralization tests and enzyme-linked immunosorbent assays against vaccine strains.
52	Results: From 23 October 2020 through 11 March 2021 we enrolled and randomized 447
53	adults. We selected sera from 95 participants at five timepoints from the first two study years
54	for testing. Among vaccinated individuals, antibody titers increased between days 0 and 30
55	against each of the vaccine strains, with substantial increases for first-time vaccinees and
56	smaller increases for repeat vaccinees, who had higher pre-vaccination titers in year 2. There
57	were statistically significant reductions in the proportion of participants achieving a four-fold
58	greater rise in antibody titer for the repeat vaccinees for A(H1N1), B/Victoria and
59	B/Yamagata, but not for influenza A(H3N2). There were no statistically significant
60	differences between groups in geometric mean titers at day 30 or the proportions of
61	participants with antibody titers \geq 40 at day 30 for any of the vaccine strains.
62	Conclusions: In the first two years, repeat vaccinees and first-time vaccinees had similar
63	post-vaccination geometric mean titers to all four vaccine strains, indicative of similar levels
64	of clinical protection. The vaccine strains of A(H1N1) and A(H3N2) were updated in year 2,

- 65 providing an opportunity to explore antigenic distances between those strains in humans in
- 66 subsequent years.
- 67
- 68 Key words: influenza; vaccination; immunogenicity; antibody
- 69

70 **INTRODUCTION**

71	The efficacy of influenza vaccines has been demonstrated in randomized trials, and annual
72	influenza vaccination campaigns prevent considerable morbidity and mortality [1].
73	Continuous viral evolution necessitates regular updates to vaccine strains, and the degree of
74	match between vaccine and circulating strains affects vaccine protection [2]. A number of
75	studies have reported that repeated annual vaccination may influence the effectiveness of the
76	influenza vaccination in the current season [3-7]. The effect of repeated vaccination on
77	immunogenicity has been less frequently assessed in multi-year randomized trials, but repeat
78	vaccination effects are also observed [8-12]. The mechanisms underlying these differences
79	are unclear, but might include "focusing" of the adaptive immune response to older strains
80	[13]. Under this model, repeated exposures boost responses to conserved and potentially less
81	protective epitopes, which might in some years reduce protection against circulating strains
82	[14, 15].

83

84 Enhanced influenza vaccines, including the recombinant hemagglutinin vaccine Flublok 85 (Sanofi Pasteur), stimulate stronger immune responses and may be able to overcome repeat 86 vaccination effects. The Flublok vaccine has two major differences with the standard egg-87 grown inactivated influenza vaccine [10, 16, 17]. First, because eggs are not used in the 88 production process for Flublok, the antigens included in the vaccine are more similar to 89 circulating viruses, circumventing the issue of egg-adapted mutations in the hemagglutinin 90 (HA) protein that can lead to antigenic mismatch [10, 18]. Second, it includes three times 91 more HA antigen than standard-dose vaccines and can therefore generate a stronger, more 92 HA-specific humoral immune response [10, 11]. Flublok has been approved by the Food and 93 Drug Administration for use in the United States in all adults ≥ 18 years of age since October 94 2014 [19]. Evidence from randomized trials have shown improved immunogenicity and

95	efficacy and a slightly lower local reactogenicity compared with standard inactivated
96	influenza vaccine in adults ≥18 years [20].

97

We designed a randomized controlled trial to explore immune responses to first-time or
repeated influenza vaccination with the Flublok vaccine, with a particular interest in the
possible occurrence of repeat vaccination effects.

101

102 **METHODS**

103 Study design

104 This study is a randomized controlled trial in adults 18-45 years of age at enrolment

105 (Clinicaltrials.gov: NCT04576377). Participants were enrolled from the general community

106 in Hong Kong, with study advertisements distributed via institutions (such as schools and

107 universities), organizations (such as professional associations), and local community centers,

and through mass promotion efforts including mass mailing to residential estates,

advertisements in newspapers and public transport, social media platforms (such as

110 Facebook), bulk emails, and invitation to and referrals from members of previous studies.

111 Individuals were eligible to participate if they were between 18 and 45 years of age, capable

112 of providing informed consent, and intending to reside in Hong Kong for at least the next two

113 years. Potential participants were excluded if they had been vaccinated against influenza in

114 the preceding 24 months, if they were included in a priority group for influenza vaccination

115 (e.g. healthcare worker, pregnant woman), if they had a diagnosed immunosuppressive

116 condition or were taking immunosuppressive medication, or if they had severe allergies or

117 bleeding conditions that contraindicated intramuscular influenza vaccination.

119	We collected a baseline 9-ml clotted blood sample from enrolled participants, and we used a
120	standardized questionnaire to collect baseline information on demographics, current health
121	status, medical history and medication use. Participants were randomized equally among five
122	equal groups using a permuted block approach with block sizes of 5 and 10, using the
123	statistical software package R. Based on the randomization scheme (Appendix Figure 1),
124	each participant would receive either influenza vaccination or placebo annually in the
125	following schedule for the first four years of the trial in the following schedule: Group 1,
126	placebo injection for all four years; Group 2, placebo for three years followed by influenza
127	vaccination in the fourth year; Group 3, placebo for two years followed by vaccination for
128	two years; Group 4, placebo in the first year and then vaccination for the subsequent three
129	years; and Group 5, vaccination in all four years. All participants would then receive
130	vaccination in the fifth and final year. Allocation to these groups was concealed using
131	REDCap [21].
132	
133	The influenza vaccine used in our trial is recombinant HA quadrivalent influenza vaccine
134	(0.5mL Flublok®, Sanofi Pasteur) for the northern hemisphere. For the 2020/21 northern
135	hemisphere influenza season, it was formulated to contain 180 mg HA per 0.5-mL dose, with
136	45 mg HA of each of the following four influenza virus strains: A/Hawaii/70/2019 (H1N1),
137	A/Minnesota/41/2019 (an A/Hong Kong/45/2019-like virus) (H3N2), B/Washington/02/2019
138	and B/Phuket/3073/2013. In 2021/22 the influenza B strains were unchanged while the
139	influenza A strains were updated to A/Wisconsin/588/2019 (H1N1) and
140	A/Tasmania/503/2020 (an A/Cambodia/e0826360/2020-like virus) (H3N2) (Appendix Table
141	1). To maintain blinding of participants, we used 0.5 ml saline placebo in syringes prepared
142	in advance and packed the vaccines and placebo doses in numbered boxes according to the

randomization scheme. Other than the nurse who conducted the injections, all other studystaff were blinded to the study intervention.

146	Following vaccination, we invited participants to return for scheduled follow-up visits at 30
147	days and 182 days after vaccination for further blood draws. In a subset of participants we
148	arranged for collection of peripheral blood mononuclear cells at baseline, day 7 and day 30,
149	and additional clotted blood samples on days 91 and 273. All participants were invited to
150	report any acute respiratory illnesses. During periods of influenza activity, we planned to
151	implement weekly active illness surveillance, collecting nasal swabs from ill participants for
152	testing by PCR and an additional blood sample 30 days after illness onset.
153	
154	Ethics
155	Written informed consent was obtained from all participants. Participants were compensated
156	with a gift voucher worth HK\$100 (US\$13) at each blood draw. The study protocol was
157	approved by the Institutional Review Boards of the University of Hong Kong (ref: UW19-
158	551) and of the University of Chicago Biological Sciences Division (ref: IRB20-0217).
159	
160	Primary and secondary outcomes
161	The primary outcome measure in this trial is the vaccine immunogenicity, measured in terms
162	of antibody titers in hemagglutination-inhibition (HAI) assays or foci reduction neutralization
163	tests (FRNTs) for each vaccine strain. We compared the proportion of participants who
164	achieved the targeted rise in antibody titre against each of the vaccine strains at 30 days. The
165	targeted rise in antibody titre is defined as a four-fold or greater rise in titer, including either a
166	pre-vaccination HAI titer <10 and a post-vaccination HAI titre ≥20 or a pre-vaccination HAI
167	titer ≥ 10 and at least a four-fold rise in post-vaccination HAI antibody titer. We also assessed

168	the geometric mean titer (GMT) ratios between the various randomized groups against each
169	of the vaccine strains at 30 days and 182 days. HAI assays were completed with A(H1N1)
170	and influenza B viruses; however; we used FRNTs to quantify antibodies against A(H3N2)
171	strains, since some contemporary A(H3N2) strains inefficiently agglutinate red blood cells
172	[10, 22]. Since the FRNT dilution series started at 20 instead of 10 due to the assay design,
173	we defined a targeted rise for antibody titers against A(H3N2) measured by FRNT as a 4-fold
174	rise to a post-vaccination titer of \geq 40.
175	
176	Other secondary outcomes specified in the protocol include additional comparisons of
177	antibody titers; analyses of cellular immunity, including transcriptional activity of immune
178	cells; comparisons of adverse reactions after vaccination; and the occurrence of influenza or
179	other acute respiratory illnesses. These secondary outcomes will be addressed in subsequent
180	reports. Of particular note, there was no influenza circulation in Hong Kong between March
181	2020 and February 2023, which included the first two years of the trial [23]. Only a few
182	influenza virus infections were detected by the local public health laboratory during this
183	period, and they were mostly in arriving travelers and children shedding live attenuated
184	vaccine virus [24, 25].

185

186 Laboratory analysis

187 Blood samples were collected in tubes for clotted blood, stored in a refrigerated container at

188 2-8°C immediately and delivered to the laboratory within two days for further processing.

- 189 Serum specimens were aliquoted and stored at -80°C prior to subsequent testing. Serum
- 190 samples were treated with receptor destroying enzyme (RDE) and tested by HAI against the
- 191 influenza A(H1N1) and B vaccine strains using a standard protocol [26]. For influenza
- 192 A(H1N1), the vaccine strains were A/Hawaii/70/2019 in 2020/21 (GISAID Accession #

193	EPI397028) and A/Wisconsin/588/2019 (GISAID Accession # EPI404460) in 2021/22. Due
194	to the inability to obtain sufficient volume of cell-grown virus stock, A/Wisconsin/588/2019
195	was eventually propagated once in eggs. A single mutation D204V was found in the egg-
196	grown stock. A comparison of antigenicity using 22 serum samples from five participants
197	showed that assay with the egg-grown stock had slightly higher sensitivity that yielded 2-fold
198	higher titers in 50% of the samples but otherwise showed good correlation with cell-grown
199	stock (Appendix Figure 2). For influenza B, ether-treated egg-grown antigens were used, and
200	the vaccine strains were B/Washington/02/2019 (GISAID Accession # EPI347829) and
201	B/Phuket/3073/2014 (GISAID Accession # EPI168822) in both years. We used a focus
202	reduction neutralization test (FRNT) for the two influenza A(H3N2) vaccine strains A/Hong
203	Kong/45/2019 in 2020/21 and A/Cambodia/e0826360/2020 in 2021/22. A/Hong
204	Kong/45/2019 HA (GISAID Accession # EPI1397376) is identical at the amino acid level to
205	A/Minnesota/41/2019 HA (GISAID Accession # EPI1487157) included in the Flublok for
206	2020/21 influenza season. However, A/Cambodia/e0826360/2020 HA (GISAID Accession #
207	EPI1837753) differs by a single amino acid substitution (N171K at antigenic site D) from
208	A/Tasmania/503/2020 HA (GISAID Accession # EPI1759269) included in the Flublok for
209	2021/22 influenza season. Both influenza A(H3N2) virus strains were generated by reverse
210	genetics using A/Puerto Rico/8/1934 internal genes [27]. FRNT assays were completed as
211	previously described [28].
212	

212

213 To estimate total binding antibody of specific IgG responses, Enzyme Linked Immunosorbent

214 Assays (ELISAs) were performed with recombinant HA (rHA) of the A(H1N1) vaccine

strains A/Hawaii/70/2019 in 2020/21 and A/Wisconsin/588/2019, and the A(H3N2) vaccine

strains A/Minnesota/41/2019 and A/Tasmania/503/2020 (Appendix Table 1). The HA stalk

217	monoclonal antibody CR9114 was used as an internal control on each plate. Expression and
218	purification of rHAs and CR9114 was performed as previously described [29].

219

220 Sample size justification

221 We aimed to enroll 820 participants into our study. This would permit us to have a sample 222 size of at least 100 participants in each of the five groups at the fourth year of follow-up, 223 allowing for an anticipated drop-out rate of 15% per year without replacement. Most of our 224 outcome measures, including both of our primary outcome measures, are based on geometric 225 mean antibody titers. In year 2, with a target sample size of 139 in each group, we expected 226 to have 80% power to identify 1.6-fold differences in GMT between groups, assuming a 227 standard deviation of $\log_2(GMT)$ of 1.8. However, due to disruption in study activities during 228 the COVID-19 pandemic we were unable to reach our target sample size, and as a 229 consequence we updated the protocol to include enrolment of an additional cohort of 530 230 participants starting in 2021/22 with a similar trial design, with participants randomized 231 across four groups instead of five, and receiving four annual doses of vaccination/placebo as 232 part of the study instead of five. Results from the second cohort with participant enrolment in 233 2021/22, named DRIVE II, will be reported in due course. For consistency, the present cohort 234 with participant enrolment in 2020/21 is named DRIVE I.

235

236 Statistical analysis

We assessed the proportion of participants who achieved a 4-fold or greater rise in antibody titre against each of the vaccine strains at 30 days, and compared these proportions between the vaccine-vaccine, placebo-vaccine and placebo-placebo groups using Fisher exact tests, pooling the three placebo-placebo groups together. We estimated GMT ratios versus the placebo group at day 30 of year 2 and compared them between first-time vaccines and repeat

vaccinees using t-tests on the log-transformed GMT ratios. Confidence intervals were
estimated using t distributions. All analyses were conducted in R version 4.2.1 (R Foundation
for Statistical Computing, Vienna, Austria). Data and R syntax will be made available after
publication.

246

247 **RESULTS**

From 23 October 2020 through 11 March 2021, 447 individuals were enrolled and received

influenza vaccination or placebo according to the randomization scheme, with 88 to 91

individuals in each arm (Figure 1). The median age of participants was 31 years, and 54%

were male, with similar characteristics across the five arms (Table 1). None of the

252 participants reported receiving influenza vaccination in the two years prior to the start of the

trial, and only 12% reported ever previously receiving influenza vaccination. We randomly

selected for laboratory analysis a subset of 15 participants from groups 1-3 (who received

255 placebo in both years), 40 participants from group 4 (placebo followed by vaccination), and

40 participants from group 5 (vaccination in both years), and noted similar characteristics in

this subset to the overall participants (Appendix Table 2).

258

Antibody titers increased between days 0 and 30 against each of the vaccine strains, with greater fold increases for first-time vaccinees compared to repeat vaccinees, while the repeat vaccinees had higher antibody titers prior to vaccination in year 2 (Figure 2). At day 30 of year 2, the GMTs were similar in the first-time vaccinees and repeat vaccinees (groups 4 and 5, respectively) for each strain analyzed (Appendix Table 4). While there were statistically significant reductions in the proportion achieving a four-fold greater rise in antibody titer for the repeat vaccinees in year 2 for A(H1N1), B/Victoria and B/Yamagata, there were no

statistically significant differences in GMTs at day 30 or the proportions with antibody titers ≥ 40 at day 30 for any of the strains (Table 2).

268

269	The A(H1N1) and A(H3N2) components of the northern hemisphere vaccine were updated
270	between 2020/21 and 2021/22. For each subtype, we examined whether vaccination with
271	one strain increased antibody titers to the other, which is a measure of cross-reactivity or
272	antigenic distance. We focused on the responses in first-time vaccinees in each of the two
273	years (i.e. group 5 in year 1 and group 4 in year 2). For A(H1N1), the year 1 GMT at day 30
274	was approximately 3.2-fold higher to the 2020/21 vaccine strain (A/Hawaii/70/2019) than to
275	the vaccine strain used the next year (A/Wisconsin/588/2019), consistent with a modest
276	antigenic distance between the two strains (Table 3). For A(H3N2), the fold-difference
277	between the day 30 GMT to the 2020/21 strain (A/Hong Kong/45/2019) and the 2021/22
278	strain (A/Cambodia/e0826360/2020) was approximately 3.1, also indicating modest
279	antigenic distance.
280	
281	The results in year 2 showed contrasting patterns, in that first-time vaccinees mounted
282	slightly stronger responses to the prior-season vaccine strains than to the current-season
283	vaccine strains. First-time vaccinees in year 2 had slightly higher day 30 GMTs to A(H1N1)
284	A/Wisconsin/588/2019 (the vaccine strain) than did first-time vaccinees receiving
285	A/Hawaii/70/2019 the previous year (60.6 vs. 40), but first-time vaccinees in year 2 had
286	approximately threefold higher titers to the previous year's strain, A/Hawaii/70/2019, than
287	to the strain with which they were vaccinated (180.6 vs. 60.6, respectively) (Table 3).
288	Similarly, first-time vaccinees in year 2 mounted approximately 1.5-fold higher titers to the
289	previous year's H3N2 strain than they did to the H3N2 strain in the vaccine (67.2 to A/Hong

291 first-time vaccinees had slightly higher absolute post-vaccination titers to the vaccine strain 292 (A/Cambodia/e0826360/2020) compared to individuals vaccinated with A/Hong 293 Kong/45/2019 the previous year (titers of 45.6 vs. 34.7), showing the strain update still led 294 to increased titers to the intended strain. 295 296 That first-time vaccinees in year 2 mounted higher titers to the prior year's influenza A 297 vaccine strains than to the current vaccine strains might reflect a strong influence of prior 298 immunity, but it could also reflect differences in receptor avidity between the strains. Viruses 299 that bind to cells with lower avidity are more easily neutralized by antibodies compared to 300 viruses that bind with higher avidity, irrespective of antigenic differences [30]. To address 301 this, we measured total HA-specific IgG antibody responses by ELISAs which are not 302 affected by differences in viral receptor binding avidities, to measure antibody binding to the 303 influenza A(H1N1) and A(H3N2) vaccine strains, with results shown in Figure 3 and Table 3. 304 We found that the year 2, geometric mean day 30 antibody levels to the current vaccine strain 305 were similar to or slightly higher than those to the previous vaccine strain in first-time 306 vaccinees, suggesting no disproportionate boosting of prior immunity targeting past strains. 307 That there were no statistically significant differences in the geometric mean post-vaccination 308 antibody levels measured by ELISA between first-time vaccinees in years 1 and 2 suggests 309 the previously reported low HAI and FRNT titers to A/Wisconsin/588/2019 and 310 A/Cambodia/e0826360/2020 thus likely arise from differences in the receptor avidity. The 311 antigenic distances implied by the ELISA data are also smaller and do not show the same 312 asymmetry as before. For instance, the amount of antibody reactive to A/Wisconsin/588/2019 313 after vaccination with A/Hawaii/70/2019 (group 5, year 1, day 30) was similar to the amount 314 of antibody reactive to A/Hawaii/70/2019 after vaccination with A/Wisconsin/588/2019

315 (group 4, year 2, day 30) (Table 3). Finally, consistent with the data from the HAI and FRNT

316	assays, there were no statistically significant differences in absolute post-vaccination
317	antibody levels measured by ELISA between first-time and repeat vaccinees in year 2.

318

319 **DISCUSSION**

320 In the second year of this five-year trial we identified reduced fold-rises in HAI titers after

321 repeat vaccination for influenza A(H1N1), B/Victoria and B/Yamagata (Figure 2). However,

322 post-vaccination GMTs were similar in repeat vaccinees and first-time vaccinees, indicating

323 that these reduced responses likely would not hinder overall protection assuming that the

324 post-vaccination HAI titer correlates with protection for Flublok [31]. During the study

325 period, public health measures used to contain COVID-19 also prevented the community

326 circulation of influenza [23], and our analysis of antibody titers is therefore unaffected by any

327 potential differences in incidence of influenza virus infections in vaccine versus placebo

328 recipients in the first year of the study that could have occurred if influenza had been

329 circulating.

330

In year 2 of our study we found that repeat and first-time vaccinees also had similar post-

332 vaccination GMTs to A(H3N2) measured by FRNT (Figure 2), indicative of similar levels of

333 clinical protection. However, there was no substantial blunting of the fold rises to A(H3N2)

in repeat vaccinees. Both groups started with low GMTs to A/Cambodia/e0826360/2020

(H3N2) in year 2 and increased those GMTs approximately 4-fold by 30 days post-

vaccination (Figure 2, Appendix Table 4). Our ELISA analyses measuring direct antibody

337 binding suggest that the observed differences in HAI and FRNT titers between groups could

be due to differences in receptor binding avidities of the viral strains used in our studies.

339

340	Both the A(H1N1) and A(H3N2) vaccine strains were updated between years 1 and 2 of the
341	study, raising opportunities to investigate the cross-reactivity of antibody titers induced by
342	vaccination. The 2020/21 vaccine induced HAI titers to A(H1N1) and FRNT titers to
343	A(H3N2) that were approximately 3-fold lower to the strains used in the 2021/22 vaccine.
344	The suggested benefits of a vaccine update were evidenced by slightly higher titers to those
345	strains among first-time vaccinees the following season compared to titers of vaccinees from
346	the 2020/21 season. However, first-time vaccinees in the 2021/22 season did not have titers
347	that were three-fold lower to strains from the 2020/21 season, as might be expected after
348	vaccination in naïve animals or associated cartographic methods. Instead, individuals
349	vaccinated in 2021/22 had approximately 3-fold and approximately 1.5-fold higher post-
350	vaccination GMTs to prior season's A(H1N1) and A(H3N2) vaccine strains. Measuring anti-
351	HA antibody responses with ELISA implied even higher cross-reactivity and limited
352	antigenic distances between viral strains used in successive years. These results suggest a
353	need to interrogate antibody responses through multiple measures and to understand how
354	each relates to protection from infection, disease and transmission.
355	
356	Our study has a number of limitations. To preserve specimens for later longitudinal analyses,
357	we have analyzed a subset of participants from the original study, and thus are limited in the
358	effect sizes we can detect in the present analysis. Future analyses might yield different results.
359	While the strains used in our serologic assays did not have 100% sequence identity with the
360	vaccine strains, the minor genetic differences likely did not affect our major conclusions.
361	Additionally, although the ELISA data suggest that antibody responses were comparable in
362	magnitude between year 1 and 2 influenza A vaccine strains, at present we cannot conclude
363	whether the contrasting HAI and FRNT results reflect strain-specific differences in receptor
364	binding avidity, neutralization potential, and/or the relative immunogenicity of the stalk and

other epitopes that are poorly measured by HAI. Understanding the roles of these factors is an
important area for further work [32].

367

- 368 In conclusion, our randomized clinical trial of repeat influenza vaccination has found that
- 369 repeat vaccination can be associated with reduced fold changes in antibody titers, but our
- 370 preliminary results show no evidence of reduced post-vaccination mean titers, consistent with
- 371 similar levels of protection after vaccination regardless of vaccination history. The apparently
- 372 low immunogenicity of influenza A vaccine strains in 2021/22 relative to the prior year may
- 373 reflect increases in receptor avidity of updated vaccine strains and deserves further study.
- 374

376 ACKNOWLEDGMENTS

- 377 The authors thank Suk Yee Chan, Tin Kin Chau, Trushar Jeevan, Pat Kaewpreedee, Ida Lam,
- 378 Erica Lau, Kelly Lee, Maggie Lo, Charlie Man, Tiffany Ng, Yammy Ng, Yvonne Ng, Eunice
- 379 Shiu, Lewis Siu, Tiffany Tavares, Ivan Tsai, Lilly Wang, Angel Wong, Irene Wong, Miyuki
- 380 Wong, Phebe Yeung, and Zoe Xiao for technical support, and Julie Au and Ada Lee for
- administrative support.

382

383 FUNDING

- 384 This project was supported by federal funds from the National Institute of Allergy and
- 385 Infectious Diseases, National Institutes of Health, Department of Health and Human Services
- 386 (grant no. U01 AI153700 and contract nos. 75N93021C00015 and 75N93021C00016), and
- 387 the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants
- 388 Council of the Hong Kong SAR Government. BJC is supported by an RGC Senior Research
- 389 Fellowship (grant number: HKU SRFS2021-7S03).

390

391 **POTENTIAL CONFLICTS OF INTEREST**

- 392 B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna,
- 393 Novavax, Pfizer, Roche and Sanofi Pasteur. S.C. has consulted for Seqirus. S.E.H. is a co-
- inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform.
- 395 S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck.
- 396 The authors report no other potential conflicts of interest.

398 **REFERENCES**

- 399 1. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United
- 400 States During the 2018-2019 Influenza Season. Clin Infect Dis **2020**; 71:e368-e76.
- 401 2. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by
- 402 subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect
- 403 Dis **2016**; 16:942-51.
- 404 3. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of Repeated Vaccination on
- 405 Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. Clin Infect Dis
- 406 **2014**; 59:1375-85.
- 407 4. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic
- 408 Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-
- 409 2015 Season. Clin Infect Dis **2016**; 63:21-32.
- 410 5. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.
- 411 Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert
- 412 Rev Vaccines **2017**; 16:1-14.
- 413 6. Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on
- 414 influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med **2019**;
- 415 **17:9**.
- 416 7. Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. Does repeated influenza
- 417 vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir
- 418 Med **2023**; 11:27-44.
- 419 8. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.
- 420 Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-
- 421 Dose Inactivated Influenza Vaccine in Older Adults. Clin Infect Dis **2016**; 62:1092-9.

- 422 9. Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated
- 423 influenza vaccination among healthcare personnel on serum hemagglutinin inhibition
- 424 antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine 2016;
- 425 34:981-8.
- 426 10. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a
- 427 glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
- 428 Proc Natl Acad Sci U S A **2017**; 114:12578-83.
- 429 11. Gouma S, Zost SJ, Parkhouse K, et al. Comparison of Human H3N2 Antibody Responses
- 430 Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines
- 431 During the 2017-2018 Season. Clin Infect Dis **2020**; 71:1447-53.
- 432 12. Leung VKY, Fox A, Carolan LA, et al. Impact of prior vaccination on antibody response
- 433 and influenza-like illness among Australian healthcare workers after influenza vaccination in
- 434 2016. Vaccine **2021**; 39:3270-8.
- 435 13. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual
- 436 influenza vaccination. PNAS **1999**; 96:14001-6.
- 437 14. Skowronski DM, Chambers C, De Serres G, et al. Serial Vaccination and the Antigenic
- 438 Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2)
- 439 Epidemics in Canada, 2010-2011 to 2014-2015. J Infect Dis **2017**; 215:1059-99.
- 440 15. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin:
- 441 Separating Good From Evil. J Infect Dis **2017**; 215:1782-8.
- 16. Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines
- 443 (Basel) **2018**; 6.
- 444 17. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza
- 445 vaccine. Influenza Other Respir Viruses **2008**; 2:211-9.

- 446 18. Yang LP. Recombinant trivalent influenza vaccine (flublok((R))): a review of its use in
- the prevention of seasonal influenza in adults. Drugs **2013**; 73:1357-66.
- 448 19. Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of
- 449 Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults
- 450 >/= 50 years of age. Vaccine **2015**; 33:6622-8.
- 451 20. Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok
- 452 in the prevention of seasonal influenza in adults. Ther Adv Vaccines **2015**; 3:97-108.
- 453 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 454 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
- translational research informatics support. J Biomed Inform **2009**; 42:377-81.
- 456 22. Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution,
- 457 and evaluation. Hum Vaccin Immunother **2018**; 14:1840-7.
- 458 23. Xiong W, Cowling BJ, Tsang TK. Influenza Resurgence after Relaxation of Public
- 459 Health and Social Measures, Hong Kong, 2023. Emerg Infect Dis **2023**; 29:2556-9.
- 460 24. Mak GCK, Lau SSY, Lam ETK, Ng KHL, Chan RCW. Domination of influenza vaccine
- 461 virus strains in Hong Kong, 2021. Influenza Other Respir Viruses **2022**; 16:1191-3.
- 462 25. Mak GCK, Lau SSY, Wong KKY, Lau AWL, Hung DLL. Low prevalence of seasonal
- 463 influenza viruses in Hong Kong, 2022. Influenza Other Respir Viruses **2023**; 17:e13123.
- 464 26. WHO Global Influenza Surveillance Network. WHO global influenza surveillance
- 465 network: Manual for the laboratory diagnosis and virological surveillance of influenza.
- 466 Available at:
- 467 https://iris.who.int/bitstream/handle/10665/44518/9789241548090_eng.pdf?sequence=1.
- 468 27. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of
- 469 Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015
- 470 Influenza Season. Cell Rep **2015**; 12:1-6.

- 471 28. Gouma S, Weirick M, Hensley SE. Antigenic assessment of the H3N2 component of the
- 472 2019-2020 Northern Hemisphere influenza vaccine. Nat Commun 2020; 11:2445.
- 473 29. Bolton MJ, Santos JJS, Arevalo CP, et al. IgG3 subclass antibodies recognize
- 474 antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent
- 475 binding. Proc Natl Acad Sci U S A **2023**; 120:e2216521120.
- 476 30. Fazekas S, Groth S. Antigenic, Adaptive and Adsorptive Variants of the Influenza a
- 477 Hemagglutinin. In: Laver, W.G., Bachmayer, H., Weil, R. (eds) The Influenza Virus
- 478 Hemagglutinin. Topics in Infectious Diseases, vol 3. Springer, Vienna.
- 479 <u>https://doi.org/10.1007/978-3-7091-4130-4_3</u>. In: Laver WG, Bachmayer H, Weil R, eds.
- 480 The Influenza Virus Hemagglutinin Topics in Infectious Diseases, vol 3. Vienna: Springer,
- 481 **1978**.
- 482 31. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant
- 483 hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized,
- 484 placebo-controlled trial. Vaccine **2011**; 29:7733-9.
- 485 32. Loes AN, Tarabi RAL, Huddleston J, et al. High-throughput sequencing-based
- 486 neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1
- 487 influenza strains. bioRxiv **2024**:2024.03.08.584176.

488

490 FIGURE LEGENDS

- 491 Figure 1. Study flow chart showing participant enrolment into the study, randomization into
- 492 five groups, interventions received, and follow up.
- 493 Footnote: *The random samples were selected from participants who provided serum
- 494 samples at these five timepoints: year 1 day 0, day 30 and day 182, and year 2 day 0 and day
- 495 **30**.

496

- 497 Figure 2. Antibody titers at various timepoints measured by hemagglutination inhibition
- 498 assay for influenza A(H1N1) and B, and by focus reduction neutralization test for influenza
- 499 A(H3N2). Measured titers are plotted for each group at 0, 30 and 182 days post-vaccination
- 500 of year 1 and at 0 and 30 days post-vaccination of year 2, and lines represent the geometric
- 501 mean titers at each timepoint. Data from group 5, receiving vaccine in both years, are shown
- 502 in red. Data from group 4, receiving placebo in year 1 and vaccine in year 2, are shown in
- 503 blue. Data from the other groups, receiving placebo in both years, are shown in gray.

504

- 505 Figure 3. Antibody levels at various timepoints measured by enzyme-linked immunosorbent
- assay for influenza A(H1N1) and A(H3N2). Measured titers are plotted at 0 and 30 days post-
- 507 vaccination in years 1 and 2, and lines represent the geometric mean antibody levels at each
- 508 timepoint. Data from group 5, receiving vaccine in both years, are shown in red. Data from
- 509 group 4, receiving placebo in year 1 and vaccine in year 2, are shown in blue. Data from the
- 510 other groups, receiving placebo in both years, are shown in gray.

511

Characteristic	Randomized allocation to receipt of placebo (P) or influenza vaccination (V)						
	in five consecutive years						
	Group 1	Group 2	Group 3	Group 4	Group 5		
	P-P-P-V	P-P-P-V-V	P-P-V-V-V	P-V-V-V-V	V-V-V-V-V		
	(n=90)	(n=91)	(n=88)	(n=90)	(n=88)		
Age at							
randomization							
18-25 years	27 (30%)	27 (30%)	34 (39%)	22 (24%)	20 (23%)		
26-35 years	32 (36%)	32 (35%)	28 (32%)	34 (38%)	34 (39%)		
36-45 years	31 (34%)	32 (35%)	26 (30%)	34 (38%)	34 (39%)		
Male sex	48 (53%)	60 (66%)	42 (48%)	46 (51%)	44 (50%)		
Reported receipt	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
of influenza							
vaccination in							
the two years							
prior to the trial							
Reported ever	11 (12%)	11 (12%)	15 (17%)	9 (10%)	9 (10%)		
receiving							
influenza							
vaccination							
prior to the trial							

513 Table 1. Characteristics of participants randomized to different vaccination strategies

514

- 516 Table 2. Antibody responses to influenza vaccination and placebo in year 2 of the trial, with 95%
- 517 confidence intervals. Antibody responses were measured by HAI for influenza A(H1N1) and B, and
- 518 by FRNT for influenza A(H3N2).

Outcome and Virus	Groups 1-3	Group 4	Group 5	p-value
	(P-P)	(P-V)	(V-V)	comparing
	(n=15)	(n=40)	(n=40)	group 5 (V-V)
				and group 4
				(P-V)
<i>Proportion with</i> \geq 4 <i>-fold rise in</i>	antibody titer fro	om day 0 to day 3	30 post-vaccinatio	on*
A/Wisconsin/588/2019	13%	78%	45%	0.005
(H1N1)	(1.6%, 40%)	(62%, 89%)	(29%, 62%)	
A/Cambodia/e0826360/2020	0%	60%	53%	0.65
(H3N2)	(0%, 21%)	(43%, 75%)	(36%, 68%)	
B/Washington/02/2019	6.7%	70%	25%	< 0.001
	(0.2%, 32%)	(53%, 83%)	(13%, 41%)	
B/Phuket/3073/2013	0%	68%	10%	< 0.001
	(0%, 22%)	(51%, 81%)	(0.3%, 24%)	

Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group

A/Wisconsin/588/2019	-	7.64	5.59	
(H1N1)		(4.0, 15)	(3.1, 10)	
A/Cambodia/e0826360/2020	-	3.97	5.65	
(H3N2)		(2.4, 6.4)	(3.6, 8.8)	
B/Washington/02/2019	-	4.14	2.83	
		(1.9, 9.2)	(1.3, 6.0)	
B/Phuket/3073/2013	-	4.65	3.91	
		(2.4, 9.1)	(2.0, 7.8)	

Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group

A/Wisconsin/588/2019	-	-	0.73	0.36
(H1N1)			(0.37, 1.43)	
A/Cambodia/e0826360/2020	-	-	1.42	0.23
(H3N2)			(0.79, 2.55)	
B/Washington/02/2019	-	-	0.68	0.23
			(0.36, 1.29)	
B/Phuket/3073/2013	-	-	0.84	0.42

(0.55, 1.29)

Proportion with antibody titer \geq 40 *at day 30 post-vaccination*

A/Wisconsin/588/2019	20%	78%	78%	1.00
(H1N1)	(4.3%, 48%)	(62%, 89%)	(62%, 89%)	
A/Cambodia/e0826360/2020	13%	75%	85%	0.40
(H3N2)	(1.7%, 40%)	(59%. 87%)	(70%, 94%)	
B/Washington/02/2019	53%	88%	88%	1.00
	(26%, 79%)	(73%, 96%)	(73%, 96%)	
B/Phuket/3073/2013	87%	100%	98%	1.00
	(60%, 98%)	(91%, 100%)	(87%, 100%)	

⁵¹⁹ *For influenza A(H1N1) and B this was defined as either a pre-vaccination antibody titer <10 and a

520 post-vaccination antibody titre \geq 20, or a pre-vaccination antibody titer \geq 10 and at least a four-fold rise

521 in post-vaccination antibody titer. For influenza A(H3N2) this was defined as either a pre-vaccination

522 antibody titer <20 and a post-vaccination antibody titre \geq 40, or a pre-vaccination antibody titer \geq 20

523 and at least a four-fold rise in post-vaccination antibody titer.

524 Table 3. Geometric mean antibody levels 30 days post-vaccination for participants receiving

Study arm and	A(H1N1)		A(H	A(H3N2)		B/Yam
year						
	A/Hawaii/70/2019	A/Wisconsin/588/2019	A/Minnesota/41/2019	A/Tasmania/503/2020	B/Washington/02/2019	B/Phuket/3073/2013
Assay	HAI	HAI [‡]	FRNT*	$FRNT^{\dagger}$	HAI	HAI
Group 5 in Year 1	127.7	40.0	107.4	34.7	61.7	273.8
Group 4 in Year 2	180.6	60.6	67.2	45.6	72.1	234.3
Assay	ELISA	ELISA	ELISA	ELISA		
Group 5 in Year 1	14400	5920	51100	34600	-	-
Group 4 in Year 2	19200	18000	48600	68500	-	-

525 vaccination for the first time in the study

- 526 Cells in bold indicate homologous responses to vaccine strains. Values for all three assays are
- 527 antibody titers.
- [‡] This virus contained an egg adaptation, D187V.

529 * The similar virus A/Hong Kong/45/2019 was used in place of A/Minnesota/41/2019 for the FRNT

530 assay

[†] The similar virus A/Cambodia/e0826360/2020 was used in place of A/Tasmania/503/2020 for the

532 FRNT assay





B/Washington/02/2019 (B/Victoria lineage)

B/Phuket/3073/2013 (B/Yamagata lineage)



